Moreover, treatment with RGFP966 alleviated T2DM-associated endothelial dysfunction and the knockdown of Nrf2 abolished HDAC3 inhibition-induced endothelial protection in T2DM both in vitro and in vivo (87). This evidence concerns the gene HDAC3 and type 2 diabetes mellitus.